Plain-English translation of NCT05761093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Researchers at the Chinese University of Hong Kong want to understand what treatment benefits and risks matter most to you and your doctor when making decisions about metastatic prostate cancer care. This study uses a survey method called a 'discrete choice experiment,' where you'll be asked about different treatment options and what you value most—such as how well a treatment works, possible side effects, or how often you need to take it. Your answers will help doctors better understand patient priorities when recommending treatments.
There are several treatment options available for metastatic prostate cancer, but doctors and patients don't always agree on which benefits and risks are most important. This study aims to close that gap by learning directly from patients and physicians what matters most in treatment decisions, especially in the Hong Kong population.
You will complete a survey in which you're presented with different treatment scenarios and asked which options you would prefer and why. The survey takes about 30–45 minutes and focuses on your personal values regarding treatment benefits (like effectiveness) and risks (like side effects). You can complete it at a clinic visit or another convenient location, and your responses will be kept confidential.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Hong Kong
Sponsor
Chinese University of Hong Kong
Enrollment target
~350 participants
Started
September 2022
Primary completion
April 2025
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in October 2026.